There’s a new player in the altcoin market that’s catching attention. This under-the-radar cryptocurrency has the potential ...

The Chinese startup has released an image-generation model called Janus-Pro, aiming to take on US rivals DALL-E 3 and Stable ...

After an extended bull run, the S&P 500 as a whole is expensively priced based on valuation metrics. So the usual chorus of warnings that the stock market is overvalued is getting louder.

The stock has now tumbled 20.1% over the past three months, while the S&P 500 has eased 0.4%. Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.

Medicare won't seek to negotiate lower prices for Eli Lilly's popular diabetes drug Mounjaro and weight loss drug Zepbound because they haven't been on the market long enough to be eligible.

Medicare drug plans are now allowed to cover Eli Lilly’s blockbuster obesity drug Zepbound for obstructive sleep apnea, the Centers for Medicare & Medicaid Services confirmed to CNBC on Jan. 8 ...

Greg Biffle has confirmed that he'd be in attendance at the 2025 Daytona 500, be it as a racer or a spectator. The former NASCAR driver, who garnered immense respect and praise for his heroic ...

Mounjaro and Zepbound, the competitor diabetes and obesity products made by American pharmaceutical company Eli Lilly, were not selected for this round of drug price negotiations. Lilly’s drug ...

Zepbound is another brand name for tirzepatide — and this one is FDA-approved for weight loss. So, how does Mounjaro work? Tirzepatide works similarly to semaglutide. The difference here is that ...

Oil futures pull back from five-month highs reached on supply concerns around U.S. sanctions and winter heating fuel demand. "Crude oil finally caved under pressure from an overbought RSI," Mizuho ...